Xact Kapitalforvaltning’s Neurocrine Biosciences NBIX Stock Holding History

Xact Kapitalforvaltning’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$1.26M	Hold	14,567	–	–	0.03%	445
2019 Q4	$1.57M	Hold	14,567	–	–	0.03%	477
2019 Q3	$1.31M	Hold	14,567	–	–	0.02%	486
2019 Q2	$1.23M	Hold	14,567	–	–	0.03%	502
2019 Q1	$1.28M	Sell	14,567 -400	-3%	-$33.4K	0.03%	493
2018 Q4	$1.07M	Buy	14,967 +1,100	+8%	+$105K	0.03%	524
2018 Q3	$1.71M	Buy	13,867 +400	+3%	+$45.4K	0.04%	445
2018 Q2	$1.32M	Buy	13,467 +1,400	+12%	+$125K	0.03%	508
2018 Q1	$1M	Buy	12,067 +3,600	+43%	+$304K	0.02%	561
2017 Q4	$657K	Buy	+8,467	New	+$578K	0.02%	605

Other funds holding NBIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Xact Kapitalforvaltning's NBIX Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Neurocrine Biosciences (NBIX) position steady in Q1 2020 at 14,567 shares worth $1.26M. The position accounts for 0.03% of the portfolio, ranked #445.

Xact Kapitalforvaltning first reported a position in NBIX in Q4 2017 and has held it in 10 quarters since. The position peaked at $1.71M in Q3 2018. 369 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

Xact Kapitalforvaltning held 14,567 shares of Neurocrine Biosciences worth $1.26M as of Q1 2020.
Xact Kapitalforvaltning left its Neurocrine Biosciences share count unchanged in Q1 2020.
Neurocrine Biosciences made up 0.03% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #445 holding.
Xact Kapitalforvaltning first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 10 quarters since.
Xact Kapitalforvaltning's Neurocrine Biosciences position peaked at $1.71M in Q3 2018.
369 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.